Mammography Device Review Warrants More Statisticians On Panel - IoM
This article was originally published in The Gray Sheet
Executive Summary
FDA's Radiological Devices Panel should include more experts in biostatistics, technology assessment and epidemiology to ensure an appropriate regulatory path for innovative breast cancer diagnostics and to eliminate the regulatory uncertainties faced by digital mammography manufacturers, the Institute of Medicine recommends in a report released March 8.